DK0792292T3 - Orphan-receptor - Google Patents

Orphan-receptor

Info

Publication number
DK0792292T3
DK0792292T3 DK96931047T DK96931047T DK0792292T3 DK 0792292 T3 DK0792292 T3 DK 0792292T3 DK 96931047 T DK96931047 T DK 96931047T DK 96931047 T DK96931047 T DK 96931047T DK 0792292 T3 DK0792292 T3 DK 0792292T3
Authority
DK
Denmark
Prior art keywords
amino acid
acid sequence
receptor
relates
disorders
Prior art date
Application number
DK96931047T
Other languages
English (en)
Other versions
DK0792292T4 (da
Inventor
George G J Kuiper
Eva Enmark
Jan-Ake Gustafsson
Original Assignee
Karobio Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0792292(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9518272.1A external-priority patent/GB9518272D0/en
Priority claimed from GBGB9605550.4A external-priority patent/GB9605550D0/en
Priority claimed from GBGB9607532.0A external-priority patent/GB9607532D0/en
Priority claimed from GBGB9609576.5A external-priority patent/GB9609576D0/en
Application filed by Karobio Ab filed Critical Karobio Ab
Application granted granted Critical
Publication of DK0792292T3 publication Critical patent/DK0792292T3/da
Publication of DK0792292T4 publication Critical patent/DK0792292T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK96931047T 1995-09-08 1996-09-09 Orphan-receptor DK0792292T4 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9518272.1A GB9518272D0 (en) 1995-09-08 1995-09-08 Orphan receptor
GBGB9605550.4A GB9605550D0 (en) 1996-03-15 1996-03-15 Orphan receptor
GBGB9607532.0A GB9607532D0 (en) 1996-04-11 1996-04-11 Orphan receptor
GBGB9609576.5A GB9609576D0 (en) 1996-05-08 1996-05-08 Orphan receptor
PCT/EP1996/003933 WO1997009348A2 (en) 1995-09-08 1996-09-09 Orphan receptor

Publications (2)

Publication Number Publication Date
DK0792292T3 true DK0792292T3 (da) 2000-02-07
DK0792292T4 DK0792292T4 (da) 2009-07-20

Family

ID=27451339

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96931047T DK0792292T4 (da) 1995-09-08 1996-09-09 Orphan-receptor

Country Status (12)

Country Link
US (2) US5958710A (da)
EP (2) EP0935000A3 (da)
JP (4) JP3131649B2 (da)
KR (1) KR100263137B1 (da)
AT (1) ATE183516T1 (da)
AU (1) AU715528B2 (da)
CA (1) CA2201098C (da)
DE (2) DE792292T1 (da)
DK (1) DK0792292T4 (da)
ES (1) ES2135249T5 (da)
GR (2) GR980300029T1 (da)
WO (1) WO1997009348A2 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor
EP0866127A3 (en) * 1997-03-17 1999-12-22 Smithkline Beecham Plc HE8AN36, a steroid hormone receptor homolog
CA2292611A1 (en) * 1997-06-10 1998-12-17 Karo Bio Ab Estrogen receptor ligands
US7157568B1 (en) * 1997-08-05 2007-01-02 American Home Products Corporation Human estrogen receptor-β
US6222015B1 (en) 1997-09-08 2001-04-24 Merck & Co., Inc. Estrogen receptor
ES2268789T3 (es) * 1997-09-08 2007-03-16 MERCK & CO., INC. Receptor de estrogeno.
GB9814620D0 (en) * 1998-07-06 1998-09-02 Karobio Ab Vasculoprotector
DE19839115A1 (de) * 1998-08-27 2000-03-09 Ihf Inst Fuer Hormon Und Fortp Klonierung und Expression von Rinder Estrogenrezeptor-beta
EP1400810A3 (en) * 1999-04-09 2005-03-02 Karo Bio Ab Estrogen receptors and bone disease
WO2000061230A2 (en) * 1999-04-09 2000-10-19 Karo Bio Ab Estrogen receptors-beta antagonism and bone diseases
WO2002064783A2 (en) * 2001-02-09 2002-08-22 Lion Bioscience Ag Novel cofactors of the estrogen receptor beta and methods of use
WO2002070697A1 (en) * 2001-03-02 2002-09-12 Lion Bioscience Ag Mammalian nuclear receptor l67 and methods of use
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
DE60220179T2 (de) 2001-11-19 2008-02-07 Eli Lilly And Co., Indianapolis Substituierte benzopyrane als selektive agonisten am östrogenrezeptor-beta
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
AU2002353076A1 (en) * 2001-12-07 2003-06-23 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor beta expression
CA2365811A1 (en) * 2001-12-21 2003-06-21 Institut De Cardiologie A new gene therapy using antisense strategy to estrogen receptors (er .alpha. and/or er .beta.) to optimize vascular healing and cardioprotection after vascular injury
WO2004019953A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
KR101092349B1 (ko) 2003-02-21 2011-12-09 다우 글로벌 테크놀로지스 엘엘씨 공액 올레핀의 단독중합법 또는 공중합법
EP1626974B1 (en) 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
US7560589B2 (en) 2003-07-28 2009-07-14 Smithkline Beecham Corporation Cycloalkylidene compounds as modulators of estrogen receptor
US20050186645A1 (en) * 2003-12-18 2005-08-25 Yehudit Amor Method for analyzing a glycomolecule
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス ６Ｈ−［１］ベンゾピラノ［４，３−ｂ］キノリン及びエストロゲン様物質としてのそれらの使用
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4981784A (en) * 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5262300A (en) * 1988-11-30 1993-11-16 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5602009A (en) * 1988-12-23 1997-02-11 The Salk Institute For Biological Studies Dominant negative chimeras of the steroid/thyroid superfamily of receptors
EP0463081B1 (en) * 1989-03-17 1998-05-20 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5438126A (en) * 1989-09-11 1995-08-01 Arch Development Corporation Human thyroid hormone receptor DNA
WO1995013373A1 (en) * 1993-11-10 1995-05-18 Arch Development Corporation Ubiquitous nuclear receptor: compositions and methods
CA2200423C (en) * 1996-03-26 2006-12-19 Sietse Mosselman Novel estrogen receptor

Also Published As

Publication number Publication date
EP0935000A3 (en) 1999-09-08
GR3031618T3 (en) 2000-01-31
DE69603827D1 (de) 1999-09-23
DE792292T1 (de) 1998-09-03
AU6988096A (en) 1997-03-27
EP0792292B2 (en) 2009-04-15
CA2201098A1 (en) 1997-03-13
JP3131649B2 (ja) 2001-02-05
WO1997009348A3 (en) 1997-04-24
WO1997009348A2 (en) 1997-03-13
US20030113803A1 (en) 2003-06-19
EP0935000A2 (en) 1999-08-11
JP2005204666A (ja) 2005-08-04
DE69603827T3 (de) 2009-11-05
CA2201098C (en) 2001-03-27
AU715528B2 (en) 2000-02-03
ES2135249T5 (es) 2009-09-10
JP2005204667A (ja) 2005-08-04
DK0792292T4 (da) 2009-07-20
US7132261B2 (en) 2006-11-07
KR100263137B1 (ko) 2000-08-01
DE69603827T2 (de) 2000-02-24
JPH11502417A (ja) 1999-03-02
EP0792292B1 (en) 1999-08-18
EP0792292A2 (en) 1997-09-03
GR980300029T1 (en) 1998-04-30
US5958710A (en) 1999-09-28
ES2135249T3 (es) 1999-10-16
JP2002010788A (ja) 2002-01-15
ATE183516T1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
DE69603827D1 (de) Waisen-rezeptor
EP1028758A4 (en) METHOD FOR TREATING PROSTATE TUMORS WITH RADIOACTIVE COMPOSITIONS
BR9915679A (pt) Composições e métodos para aumentar a mineralização óssea
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
BR9710636A (pt) Análogo de somatostatina ciclizada da espinha dorsal, uso do mesmo, composição farmacêutica,e , processo de tratamento de distúrbios endócrinos, neoplasmas ou distúrbios metabólicos.
BR9712589A (pt) Conjugado, composição farmacéutica, processos para tratar cáncer de próstata, para tratar hiperplasia prostática benigna, e, para fazer uma composição farmacêutica.
MXPA00012586A (es) Glicosulfopeptidos y metodos de sintesis y uso de los mismos.
AU6045398A (en) Androgen synthesis inhibitors
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
PL328858A1 (en) Immunogenous peptides
DE60045751D1 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
DE69809726D1 (de) Substituierte analoge von indol-3-carbinol und von diindolmethan als antiestrogene
WO1996035784A3 (de) Chromatin-regulatorgene
Banerjee et al. Distinct colchicine binding kinetics of bovine brain tubulin lacking the type III isotype of beta-tubulin
DE69720996D1 (de) Neue pharmazeutische zusammensetzungen von steroid-nitratester zur verwendung als enzündungshemmer
LEVI-MONTALCINI et al. Hormonal control of the NGF content in the submaxillary glands of mice
DE69921130D1 (de) Verfahren und stoffe zur behandlung des prostatakarzinomes
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
IL128872A0 (en) TNF-beta-like protein for treating prostate cancer and related nucleic acid molecules pharmaceutical compositions and methods
DK0988040T3 (da) Anvendelse af glucosamin og glucasamin-derivater til hurtig lindring af klöe eller lokaliseret smerte
BR9808784A (pt) Método para o tratamento de doença mental em mamìferos e uma composição para o mesmo
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
NO972313D0 (no) Peptider som er i stand til å binde til GAP-protein-SH3-området, nukleotid-sekvenser som koder for dette samt fremstilling og bruk derav
Miller et al. Elevated intrinsic reactivity of seryl hydroxyl groups within the linear peptide triads His-Xaa-Ser or Ser-Xaa-His